Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Department of Gynaecological Oncology

12 publications found

Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H (2020)
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
EBioMedicine, 57, 102841 (in press)
DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139

Harter P, Pautier P, Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Petru E, Heitz F, Sehouli J, Degregorio N, Wimberger P, Burges A, Cron N, Ledermann J, Lorusso D, Paoletti X, Marme F (2020)
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Int J Gynecol Cancer (in press)
DOI 10.1136/ijgc-2020-001572, PubMed 32606097

Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, Lyng H (2020)
MR Imaging Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
Cancer Res (in press)
DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004

Kargo AS, Coulter A, Lindemann K, Jensen PT, Hjøllund NH, Mosgaard BJ, Steffensen KD (2020)
Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol
Int J Gynecol Cancer (in press)
DOI 10.1136/ijgc-2020-001528, PubMed 32586892

Koklesova L, Liskova A, Samec M, Qaradakhi T, Zulli A, Smejkal K, Kajo K, Jakubikova J, Behzadi P, Pec M, Zubor P, Biringer K, Kwon TK, Büsselberg D, Sarria GR, Giordano FA, Golubnitschaja O, Kubatka P (2020)
Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine
EPMA J, 11 (2), 261-287
DOI 10.1007/s13167-020-00210-5, PubMed 32547652

Lindemann K, Martinsson L, Kaasa S, Lindquist D (2020)
Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
Acta Oncol, 59 (6), 636-643
DOI 10.1080/0284186X.2020.1744717, PubMed 32238040

Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2020)
DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
Radiat Oncol, 15 (1), 79
DOI 10.1186/s13014-020-01526-2, PubMed 32293487

Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, Kristensen G, Ottevanger PB, Aravantinos G, Miller A, Boere IA, Fruscio R, Reyners AKL, Pujade-Lauraine E, Harkin A, Pignata S, Kagimura T, Welch S, Paul J, Karamouza E, Glasspool RM, Gynecologic Cancer InterGroup (GCIG) Meta-analysis Committee (2020)
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
JAMA Netw Open, 3 (1), e1918939
DOI 10.1001/jamanetworkopen.2019.18939, PubMed 31922558

Salminen L, Nadeem N, Rolfsen AL, Dørum A, Laajala TD, Grènman S, Hietanen S, Heinosalo T, Perheentupa A, Poutanen M, Bolstad N, Carpén O, Lamminmäki U, Pettersson K, Gidwani K, Hynninen J, Huhtinen K (2020)
Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
J Appl Lab Med, 5 (2), 263-272
DOI 10.1093/jalm/jfz012, PubMed 32445385

Vistad I, Bjørge L, Skeie-Jensen T (2020)
Need for change in cancer follow-up
Tidsskr Nor Laegeforen, 140
DOI 10.4045/tidsskr.20.0281, PubMed 32323956

Vistad I, Lindemann K, Bentzen AG, Dahl AA, Steen R, Kiserud C (2020)
Preferences for follow up in long-term survivors after cervical cancer
Acta Obstet Gynecol Scand
DOI 10.1111/aogs.13855, PubMed 32232835

Zubor P, Dankova Z, Kolkova Z, Holubekova V, Brany D, Mersakova S, Samec M, Liskova A, Koklesova L, Kubatka P, Bujnak J, Kajo K, Mlyncek M, Giordano FA, Golubnitschaja O (2020)
Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare
Cancers (Basel), 12 (5)
DOI 10.3390/cancers12051292, PubMed 32443784

 
Page visits: 410633